CLO20-039: Patient (pt)-Reported Outcomes (PRO) in Patients With HER2-Negative Locally Advanced/Metastatic Breast Cancer (LA/mBC) and a Germline BRCA1/2 Mutation (gBRCA1/2 mut) Receiving Talazoparib vs. Physician’s Choice of Chemotherapy (PCT): A Focus on EMBRACA Racial Subgroups

Authors:
Sara A. Hurvitz University of California Los Angeles, Los Angeles, CA

Search for other papers by Sara A. Hurvitz in
Current site
Google Scholar
PubMed Close
 MD
,
Ruben G. W. Quek Pfizer, Inc., San Francisco, CA

Search for other papers by Ruben G. W. Quek in
Current site
Google Scholar
PubMed Close
 PhD
,
Helen Bhattacharyya Pfizer, Inc., San Francisco, CA

Search for other papers by Helen Bhattacharyya in
Current site
Google Scholar
PubMed Close
 PhD
,
Johannes Ettl Technische Universität München, Munich, Germany

Search for other papers by Johannes Ettl in
Current site
Google Scholar
PubMed Close
 MD
,
Anthony Gonçalves Aix-Marseille Université, Marseille, France

Search for other papers by Anthony Gonçalves in
Current site
Google Scholar
PubMed Close
 MD, PhD
, and
Hope S. Rugo UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Search for other papers by Hope S. Rugo in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 18: Issue 3.5
Online Publication Date:
20 Mar 2020
DOI:
https://doi.org/10.6004/jnccn.2019.7390
Restricted access

Corresponding Author: Sara A. Hurvitz, MD
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
Copyright:
Copyright © 2020 by the National Comprehensive Cancer Network 2020
Article Category:
Abstract
Print Publication Date:
20 Mar 2020
Online Publication Date:
20 Mar 2020

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2035 1084 78
PDF Downloads 280 0 0
EPUB Downloads 0 0 0